StockNews.AI
XERS
StockNews.AI
166 days

Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance

1. Xeris reported record revenue of $203 million for 2024. 2. 2025 financial guidance reflects continued growth potential.

Earnings
+11.27%Current Return
VS
-1.36%S&P 500
$3.7703/06 07:35 AM EDTEvent Start
$4.19503/07 01:56 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

The strong revenue performance is likely to boost investor confidence. Historical examples show that strong earnings often correlate with stock price increases.

How important is it?

The reported revenue can attract new investors and speculation, boosting XERS's market position. Positive guidance also indicates potential for further growth.

Why Short Term?

Immediate positive reactions can be expected in response to strong earnings reports. Investors often react quickly to financial results.

Related Companies

AMGNVRTXREGN
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full-year ended December 31, 2024 and provides full-year 2025 financial guidance. “The Xeris team executed an exceptional 2024 with record revenue topping $203 million,” said John Shannon, Xeris' Chief Ex.

Related News